

Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- ACOG says it will no longer accept federal funding
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- Bhattacharya: New grant review criterion is “not political”
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”